South Korean vaccine and biotech innovator SK bioscience has announced its leadership of the Research Optimization & Trial Outcome Recommender (ROTOR) project, an AI-powered evidence synthesis and clinical development decision-support platform initiative. Funded by the Bill & Melinda Gates Foundation, this global collaborative initiative involves technical contributions from the global health nonprofit PATH, global technology consulting firm Slalom, and SK AX. The ROTOR platform is uniquely designed to harness artificial intelligence to aggregate and analyze diverse clinical, immunogenicity, and scientific datasets generated throughout the vaccine development pipeline, effectively mitigating the immense financial risks and scientific uncertainties typically associated with transitioning from Phase II to large-scale Phase III clinical trials.
Also Read: Boltz Partners with Takeda to Deploy Frontier Biomolecular AI Models
Initially developed and validated using rotavirus vaccine datasets from SK bioscience and PATH, the scalable platform aims to expand to other disease areas, thereby enhancing the research and development capabilities of vaccine developers in low- and middle-income countries (LMICs) while accelerating global public health equity. This initiative aligns with SK bioscience’s broader digital transformation strategy, which incorporates AI-driven experimental design systems and digital twin technologies to optimize manufacturing efficiency and shrink development timelines. Highlighting the initiative’s strategic vision, Jaeyong Ahn, CEO of SK bioscience stated, “This project represents a new approach to reducing uncertainty in vaccine development through AI and enabling more scientific and efficient decision-making. Through this consortium, we aim to drive innovation in vaccine R&D while contributing to improved vaccine access worldwide.”